40 mg Laninamivir Octanoate + 80 mg Laninamivir Octanoate + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Influenza
Conditions
Influenza
Trial Timeline
May 1, 2013 → May 1, 2014
NCT ID
NCT01793883About 40 mg Laninamivir Octanoate + 80 mg Laninamivir Octanoate + Placebo
40 mg Laninamivir Octanoate + 80 mg Laninamivir Octanoate + Placebo is a phase 2 stage product being developed by Vaxart for Influenza. The current trial status is completed. This product is registered under clinical trial identifier NCT01793883. Target conditions include Influenza.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01793883 | Phase 2 | Completed |
Competing Products
20 competing products in Influenza